Evidence map›Paper›PMID 40454406›Full record

ArticleBlood neoplasia2025

Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemia.

Olivia M Depies, Qianqian Guo, Yuan Gao, Sutapa Sinha, Zhenqing Ye, Weiguo Han, Kari G Rabe, Mingma S Hoel, Heather C Darby, Chuanhe Yu and 5 more

Abstract read
In one paragraph

Article in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Olivia M DepiesDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Qianqian GuoDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Yuan GaoDepartment of Pharmacology, Case Western Reserve University, School of Medicine, Cleveland, OH.
Sutapa SinhaDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Zhenqing YeGreehey Children's Cancer Research Institute, The University of Texas Health Science Center at San Antonio, San Antonio, TX.
Weiguo HanDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Kari G RabeDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN.
Mingma S HoelDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Heather C DarbyDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Chuanhe YuThe Hormel Institute, University of Minnesota, Austin, MN.
Esteban BraggioDepartment of Hematology and Oncology, Mayo Clinic, Phoenix, AZ.
Sameer A ParikhDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Susan L SlagerDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Neil E KayDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Zhiquan WangDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI Fergus Joseph Couch · 2005 to 2026
$49.9M
Outcomes for CLL patients treated with novel therapyR01CA251801 · NCI · MAYO CLINIC ROCHESTER · PI Neil E Kay, Saad J. Kenderian · 2021 to 2026
$4.0M
NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA116201NCI NIH HHS R01 CA251801
6 · The paper itself

Abstract

Epigenetic alterations have been found in chronic lymphocytic leukemia (CLL), but the functional importance of these changes remains underexplored. Here, we characterized the genome-wide histone modification landscapes of CLL using patient-derived samples across the disease course. Compared with normal B cells, we found that the enhancers specifically lost in CLL B cells are associated with the downregulation of genes involved in immune response. Importantly, these lost enhancers exhibit an increased level of heterochromatin marks, including H3K9me3 and H3K27me3. Using the

Identifiers

PMID40454406
PMCPMC12082150

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.